Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093976 · ClinicalTrials.gov registry record · Phase 2
Marinol in Trichotillomania or Obsessive Compulsive Disorder
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01093976 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 14 participants.
The verdict
NCT01093976, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in individuals with obsessive-compulsive disorder (OCD) or the obsessive-compulsive spectrum disorders, trichotillomania (TTM) or pathological skin picking (PSP). Fifteen patients with OCD, TTM, or PSP will receive 12 weeks of open-label treatment with dronabinol. The hypothesis to be tested is that dronabinol will be effective and well tolerated in patients with these disorders. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Interventions
- DRUG Dronabinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093976
The ClinicalTrials.gov registry entry for NCT01093976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dronabinol is the first listed.
NCT01093976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093976 about?
NCT01093976 is a clinical study titled "Marinol in Trichotillomania or Obsessive Compulsive Disorder". The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in individuals with obsessive-compulsive disorder (OCD) or the obsessive-compulsive spectrum disorders, trichotillomania (TTM) or pathological skin picking (PSP). Fifteen patients with OCD, TTM, or PSP will receive 1...
What is the current status of trial NCT01093976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-04. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01093976?
The interventions under investigation include: Dronabinol (DRUG).
Who is sponsoring clinical trial NCT01093976?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.